IL164020A0 - A process for the preparation of amorphous hmg-coareductase inhibitors - Google Patents

A process for the preparation of amorphous hmg-coareductase inhibitors

Info

Publication number
IL164020A0
IL164020A0 IL16402002A IL16402002A IL164020A0 IL 164020 A0 IL164020 A0 IL 164020A0 IL 16402002 A IL16402002 A IL 16402002A IL 16402002 A IL16402002 A IL 16402002A IL 164020 A0 IL164020 A0 IL 164020A0
Authority
IL
Israel
Prior art keywords
preparation
hmg
amorphous
amorphous hmg
coareductase inhibitors
Prior art date
Application number
IL16402002A
Other languages
English (en)
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd filed Critical Biocon Ltd
Publication of IL164020A0 publication Critical patent/IL164020A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL16402002A 2002-03-18 2002-03-18 A process for the preparation of amorphous hmg-coareductase inhibitors IL164020A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2002/000045 WO2003078379A1 (fr) 2002-03-18 2002-03-18 Inhibiteurs de hmg-coa reductase amorphe avec taille souhaitee des particules

Publications (1)

Publication Number Publication Date
IL164020A0 true IL164020A0 (en) 2005-12-18

Family

ID=27840281

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16402002A IL164020A0 (en) 2002-03-18 2002-03-18 A process for the preparation of amorphous hmg-coareductase inhibitors

Country Status (16)

Country Link
US (1) US7230120B2 (fr)
EP (1) EP1485343B1 (fr)
JP (1) JP4308021B2 (fr)
KR (1) KR100828653B1 (fr)
AT (1) ATE452871T1 (fr)
AU (1) AU2002247944B2 (fr)
BR (1) BR0215644A (fr)
CA (1) CA2479005C (fr)
CZ (1) CZ2004943A3 (fr)
DE (1) DE60234868D1 (fr)
ES (1) ES2338530T3 (fr)
HR (1) HRP20040967A2 (fr)
HU (1) HUP0500074A3 (fr)
IL (1) IL164020A0 (fr)
NZ (1) NZ535910A (fr)
WO (1) WO2003078379A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
ATE545629T1 (de) 2004-03-17 2012-03-15 Ranbaxy Lab Ltd Verfahren zur herstellung von atorvastatin- calcium in amorpher form
EP1799641A4 (fr) * 2004-10-05 2007-09-19 Biocon Ltd Procede de preparation de fluvastatine sodique amorphe
CA2582087A1 (fr) * 2004-10-18 2006-04-27 Teva Pharmaceutical Industries Ltd. Procede d'elaboration d'hemicalcium d'atorvastatine amorphe par dissolution du sel dans un solvant organique qui est un melange d'alcool et de cetone et/ou d'ester et elimination du solvant
AU2005298383A1 (en) * 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
CA2547216A1 (fr) 2005-09-21 2007-03-21 Renuka D. Reddy Procede de recuit de l'atorvastatine amorphe
EP1905424A3 (fr) * 2006-02-02 2008-04-30 Ranbaxy Laboratories Limited Procédé de preparation d'une composition pharmaceutique comprenant des particules de statine stabilisées
US8219173B2 (en) 2008-09-30 2012-07-10 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US7834195B2 (en) 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
CA2694378A1 (fr) * 2007-07-27 2009-02-05 Cipla Limited Compositions pharmaceutiques et leur procede de preparation
WO2010066846A2 (fr) * 2008-12-11 2010-06-17 Dsm Ip Assets B.V. Procédé pour isoler de l'atorvastatine

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
HRP960312B1 (en) 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
SI20305A (sl) * 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
EP1163203A1 (fr) * 1999-03-08 2001-12-19 Merck & Co., Inc. Sel de calcium hydrate et cristallin de simvastatine d'acide ouvert en dihydroxy
US6646133B1 (en) * 2000-10-17 2003-11-11 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
HU226640B1 (en) * 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
CA2421018A1 (fr) * 2000-09-06 2002-03-14 Merck & Co., Inc. Sel d'acide ouvert dihydroxy de simvastatine
CA2427255A1 (fr) 2000-11-16 2002-06-06 Teva Pharmaceutical Industries Ltd. Hydrolyse d'esters d'acide [r(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta. -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoique au moyen d'hydroxyde de calcium hydroxide
US6777552B2 (en) 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
CN1610657A (zh) 2001-07-06 2005-04-27 西巴特殊化学品控股有限公司 制备用于合成他汀类衍生物、特别是7－氨基3,5－二羟基庚酸衍生物的中间体的方法,及其中间体
HUP0401014A2 (hu) 2001-07-06 2004-08-30 Teva Pharmaceutical Industries Ltd. Eljárás 7-amino-szin-3,5-dihidroxi-heptánsavszármazékok előállítására, 6-ciano-szin-3,5-dihidroxi-hexánsav származékokon keresztül
DK1404642T3 (da) 2001-07-06 2010-05-17 Basf Se Fremgangsmåde til fremstillimg af 7-amino-syn-3,5-dihydroxyheptansyrederivater, mellemprodukter derfor og fremgangsmåder til deres fremstilling
HRPK20040255B3 (en) 2001-08-16 2006-02-28 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
BR0307720A (pt) 2002-02-14 2005-01-25 Ranbaxi Lab Ltd Formulações de atorvastatina estabilizadas com adições de metal alcalino, método para produzir uma formulação farmacêutica e estabilizar dita formulação

Also Published As

Publication number Publication date
KR20040101279A (ko) 2004-12-02
US20040186162A1 (en) 2004-09-23
AU2002247944B2 (en) 2009-05-21
JP4308021B2 (ja) 2009-08-05
CA2479005A1 (fr) 2003-09-25
CA2479005C (fr) 2012-05-22
DE60234868D1 (de) 2010-02-04
KR100828653B1 (ko) 2008-05-09
ATE452871T1 (de) 2010-01-15
US7230120B2 (en) 2007-06-12
AU2002247944A1 (en) 2003-09-29
EP1485343A4 (fr) 2006-05-31
CZ2004943A3 (cs) 2005-02-16
HUP0500074A3 (en) 2005-07-28
WO2003078379A1 (fr) 2003-09-25
ES2338530T3 (es) 2010-05-10
HRP20040967A2 (en) 2005-06-30
EP1485343B1 (fr) 2009-12-23
EP1485343A1 (fr) 2004-12-15
HUP0500074A2 (hu) 2005-05-30
BR0215644A (pt) 2004-12-21
JP2005520830A (ja) 2005-07-14
NZ535910A (en) 2006-04-28

Similar Documents

Publication Publication Date Title
TW200510002A (en) Solid pharmaceutical preparation
DE60239428D1 (fr)
AU2003211576A1 (en) Histone deacetylase inhibitors and process for producing the same
WO2005014539A3 (fr) Inhibiteurs nouveaux de l'hmg-coa reductase a base de pyrrole
EP1684754A4 (fr) Inhibiteurs de la reductase hmg-coa et procede associe
AU2003291356A1 (en) Methods and compositions for treating cancer using proteasome inhibitors
IL164020A0 (en) A process for the preparation of amorphous hmg-coareductase inhibitors
AU2003260345A1 (en) 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
IL192208A0 (en) Methods for improving the pharmacokinetics of hiv integrase inhibitors
TW200638950A (en) Dosage forms of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
AU2003269421A1 (en) Hiv-integrase inhibitors, pharmaceutical compositions, and methods for their use
AU2003250172A1 (en) Compositions comprising hmg-coa reductase inhibitor
TW200509993A (en) Process for forming amorphous atorvastatin
AU2003253773A1 (en) Methods and apparatus for forming anastomotic sites
WO2007075870A3 (fr) Procedes pour derives de taxane et intermediaires utiles correspondants
TW200724688A (en) Process for producing atorvastatin, pharmaceutically acceptable salts thereof and intermediates thereof
MX2007004722A (es) Procedimiento para formar atorvastatina amorfa.
BRPI0417138A (pt) n-alquil-pirroles como inibidores de hmg-coa-redutase
BRPI0506865A (pt) inibidores de hmg-coa redutase inusitados, baseados em imidazóis
WO2007011405A3 (fr) Dispositif et procede a utiliser pour la detection et la caracterisation de micro-organismes et de microparticules
IL157597A0 (en) Diaminoquinazoline esters for use as dihydrofolate reductase inhibitors
WO2007022044A3 (fr) Combinaison de composes organiques
WO2007010013A3 (fr) Composes organiques
AU2004269436A8 (en) Method, device and software for querying and presenting search results
AU2003903211A0 (en) Method of, and Apparatus for, Forming an Article and an Article Formed Thereby

Legal Events

Date Code Title Description
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees